
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros Corporation is positioned positively due to the promising results of its drug candidate, narsoplimab, demonstrating statistically significant survival advantages in patients with transplant-associated thrombotic microangiopathy (TA-TMA), which enhances the clinical foundation of its therapy amid competitive market dynamics. Additionally, the company has shown favorable Phase 2 results for zaltenibart in treating paroxysmal nocturnal hemoglobinuria, indicating its potential for safety, tolerability, and superiority over existing alternative pathway inhibitors, thus opening avenues for considerable market potential. The successful developments in both therapeutic areas underscore Omeros's ability to navigate the clinical landscape effectively, presenting a robust outlook for the company's financial trajectory as it continues to advance its innovative portfolio.
Bears say
Omeros Corp has faced significant operating losses, with no expectation of achieving profitability in the foreseeable future, primarily due to the high costs associated with research and development for its drug candidate, narsoplimab. The company operates in niche disease markets, with low patient prevalence, which may hinder its commercial viability despite a pressing unmet medical need in conditions like thrombotic microangiopathy. Additionally, there remains considerable uncertainty surrounding the FDA approval of narsoplimab, attributed to an unconventional development trajectory, limited clinical trial data, and a prolonged timeframe since the last review without new supporting evidence.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares